Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation

featured image
Year: 2021

Phelinun is in development as a conditioning treatment prior to allogenic haematopoietic stem cell transplantation (HSCT) for various haematological diseases in children and adults. HSCT involves infusing stem cells from a donor into a patient whose bone marrow is damaged or defective. Conditioning treatment prior to HSCT is required in order to kill cancer cells, remove existing bone marrow from the patient and suppress the immune system, to reduce the risk of rejection from the transplant. Conditioning treatment is essential for a successful transplant but there are major associated side effects, including increased mortality. Therefore, there is a need for less toxic conditioning treatments.
Phelinun contains the active ingredient melphalan, which is already used to treat various cancers. It is also intended for the additional use of conditioning prior to HSCT. Phelinun is given by intravenous (IV) infusion and works by interfering in cellular processes, resulting in cell death. If licensed, phelinun will offer an additional treatment option for various cancers and conditioning prior to HSCT.